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Abstract
Public confidence in clinical trials has been eroded by data suppression, misrepresentation and manipulation. 
Although various attempts have been made to achieve universal trial registration- e.g., Declaration of Helsinki, WHO 
clinical Trial Registry Platform (WHO ICTRP), the International Committee of Medical Journal Editors requirement- they 
have not succeeded, probably because they lack the enough power of enforcement.
Legislation appears to be the most efficient and effective means to ensure that all researchers register their trials and 
disseminate their data accurately and in a timely manner. We propose that a global network be established. This could 
be accomplished in two steps. The first step is to legislate about trial registration and data transparency, such as USA's 
FDAAA Act 2007; and the second step to establish a global network to ensure uniform, international consistency in 
policy and enforcement of trial registration and data transparency.
Introduction
P ubli c c o nfide nc e  in c li nical  t ria ls has  bee n e r oded by
high-profile scandals involving alleged data suppression,
misrepresentation and manipulation [1-6]. Such miscon-
duct has serious implications for the health care system,
and also violates the ethical responsibilities of researchers
and sponsors [7,8]. These scandals have highlighted the
need and generated the impetus to increase data trans-
parency in order to restore public confidence in clinical
trials [9,10]. Unfortunately, the trial registration cannot
adequately ensure full data transparency.
Trial registration
The concept of trial registration was first mentioned by
Simes RJ in 1986[11]. At that time, the major purpose was
to reduce publication bias [12]. The first registry http://
ClinicalTrials.gov was launched under Section 113 of the
Food and Drug Administration Modernization Act
(FDAMA 113) of the United States (US) in 1997 [13].
Unfortunately, despite legislation, many drug trials in the
US were not registered [14]. The inadequate reporting in
the US gained attention in 2004 when scandals arose over
selective reporting of trial data for selective serotonin
reuptake inhibitors (SSRIs) [15] and rofecoxib [16]. The
SSRIs case resulted in the New York State attorney suing
GlaxoSmithKline (GSK) company over its 'illegal and
deceptive' reporting by suppressing reports of suicidal
thinking among patients and misleading doctors into
overprescribing the antidepressant paroxetine to children
[17]. Eventually, the New York State Attorney General's
office reached an agreement with GSK in which GSK was
required to maintain an online clinical trials registry that
included information about safety and efficacy, type and
severity of side effects, midstream methodological
changes and early terminations [18]. Unfortunately, this
settlement did not change the registration requirements
for trials of other US drug companies or for trials that
were not supported by drug companies. Of course, it had
little effect on trials conducted in other countries.
The first international policy on trial registration was
introduced by the International Committee of Medical
Journal Editors (ICMJE) in October 2004[19]. The policy
required that trials be registered at the http://ClinicalTri-
als.gov site before enrolment of patients in order for the
manuscript to be considered for publication in ICMJE
journals. This action had 'mandatory' enforcement
power, and the number of trial registrations at http://
www.ClinicalTrials.gov increased dramatically after the
ICMJE announcement [20]. In 2007 ICMJE updated their
statement to call for prospective registration in the
ICMJE-endorsed registry for publication in any of their
member journals [21]. However, publication in ICMJE
journals is sometimes not an objective for conducting a
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clinical trial, therefore the policy has limited power to
secure universal trial registration.
In the Ministerial Summit on Health Research that took
place in Mexico City, Mexico, in November 2004, the
World Health Organization (WHO) called for members
to "establish a voluntary platform to link clinical trials
registers in order to ensure a single point of access and the
unambiguous identification of trials with a view to
enhancing access to information by patients, families,
patient groups and others". Currently, the WHO ICTRP,
established in August 2005, is composed of Primary Reg-
istries (currently 10) and Partner Registries; and it pro-
vides an international platform that enables researchers,
health practitioners, consumers, journal editors and
reporters to search more easily and quickly for informa-
tion on clinical trials [22]. But WHO ICTRP is still a vol-
untary system, relying on the consciences of researchers
for compliance, as it says, 'The registration of all interven-
tional trails is a scientific, ethical and moral responsibil-
ity.'
The Ottawa Statement, which was published in 2005,
required that registration and early public release of accu-
rate information about all trials are necessary to fulfill
ethical obligations to participants; and all trial results
should be registered and made publicly available, along
with sufficient protocol information to enable critical
assessment of their validity[23]. However, the Statement
only recognizes that trial registration is an ethical obliga-
tion. Unfortunately, previous scandals clearly demon-
strate that ethical power alone is not enough to persuade
all trial researchers to register their trials.
In 2008, the World Medical Association announced in
the revised Declaration of Helsinki that "Every clinical
trial must be registered in a publicly accessible database
before recruitment of the first subject" [24]. In this way the
World Medical Association has unequivocally established
its position that public registration of clinical trials is nec-
essary. If the ethics committees, at every research institu-
tion in every country, would strictly follow the
Declaration, it would represent a necessary but not suffi-
cient condition toward securing universal trial registra-
tion. One big problem is that not all trials pass through a
strict ethics committee approval process [25], and also it
is pending question whether Declaration of Helsinki
could be completely followed by the ethics committee.
In summary, the current requirement about trial regis-
tration, majorly from ethical aspects and publication pur-
pose, does not have the universal power to make sure all
trials registered.
Data transparency
The purpose of trial registration is to make sure all data
about a trial is available generally to the public and specif-
ically to health care professionals. It is an original motiva-
tion behind the trial registration, especially the 2004 call
for a central registry. But trial registration itself does not
automatically ensure data transparency. Even if a trial
registration requirement is implemented successfully in
each country in the world, it still cannot secure data
transparency. The reason is that registration requires
only minimal information; generally it simply establishes
there is a trial currently underway or about to start some-
where in this world. After registration, trial investigators
should update their entries, especially releasing the trial
results in an accurate and timely manner. But recently
studies showed that trial registration does not ensure the
timely availability of accurate trial results [26]. In the
study, 57 endometriosis-related clinical trials registered
at ClinicalTrials.gov were found, with 25 listed as com-
pleted, and 2 as suspended; leaving 30 unaccounted.
Among 57 trials, there are 15 completed phase II/III tri-
als, yet only three of the 15 trials (20%) had published
their results. The remaining 12 (80%) studies so far have
not published their findings even though some of these
trials were completed as long as seven years. Clearly, trial
registration requirements do not result in data transpar-
ency automatically. A full requirement for trail registra-
tion should let the trialists i) to register a trial before
starting the patient recruitment, ii) to update the modifi-
cation of trial protocol if any, and iii) to disseminate the
trial results accurately and in a time manner. Therefore,
trial registration should have a package of requirements
from the start to the end, thus to make the public have
possibility to know the whole profile of a trial.
Legislation
Recent past years have witnessed the ineffectiveness of
voluntary, partly-mandatory, and ethical requirements
for trial registration. Such requirements cannot ensure
that all trials are registered and that data are transpar-
ently reported. The major reason is that these require-
ments are lack of enough enforcement for trialists. Only a
mandatory system can effectively ensure global trial reg-
istration and data transparency. The best mandatory sys-
tem is legislation. Only legislation has universal power to
ensure that all trial researchers register their trials and
disseminate their data timely and concisely. The agree-
ment between the New York State Attorney General'
office and GSK company about trial is a good example.
After the SSRIs scandals, the US Congress enacted the
Food and Drug Administration (FDA) Amendments Act
of 2007 (FDAAA) in 2007, which mandates public regis-
tration and disclosure of results of 'applicable' clinical tri-
als of drugs, biologics and devices on http://
www.Clinicaltrials.gov[27]. Starting from December
2007, results disclosure occurred in three stages initially
with links to information from the FDA and NIH about
FDA-approved products as well as Medline citations. ABian and Wu Trials 2010, 11:64
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Basic Results Database appeared in September 2008, and
an Expanded Results Database will appear in 2010. The
Act FDAAA 2007 requires that all results for trials of
FDA-approved products must be posted within 12
months of trial completion. These requirements targeted
"applicable" trials of drugs and devices subject to FDA
regulation, but excluded Phase I drug trials and device
feasibility studies. This new law requires researchers not
only register trials but also put results into the database
on time. Clearly, the Act has the power to require
researchers in the US to register their trials. But limita-
tions exist in that not all FDA-approved drug trials need
to be registered. Also, this requirement may have an
effect on publication bias [28]. Some nations such as
India, not just USA, have made great efforts to legislate,
thus to make sure all trials be registered [29]. We hope to
see more and more nations take necessary actions for this
purpose.
Global network
Legislation for the trial registration in a few countries is
not enough and a global network for the trial registration
s h o u l d  be  e s t a b l is h ed .  F i r s t,  ea c h  c o u n t ry  t h a t  h as  t h e
ability to conduct clinical trials should have such legisla-
tion. It is conceivable that if one country requires trial
registration and data transparency, while another country
does not, then there is a possibility that many, if not most,
clinical trials may shift to that country. Second, in order
to have a universal mandatory system for trial registration
and data transparency, based on the requirements from
WHO ICTRP, ICMJE, and the Declaration of Helsinki, a
network involving all countries should be established to
ensure uniform, international consistency in policy and
enforcement of trial registration and data transparency.
This network could be established in regional basis, and
a global network could be based on these regional net-
works. It should be emphasized that local effort from one
country to a region is the basis for the global network. In
this process, WHO may form an international advisory
committee to provide consultation for each country and
to help them to meet this aim. Further, this advisory com-
mittee can be charged with the responsibility of monitor-
ing the implementation of such legislation through
different approaches, such as publishing white paper of
trial registration annually, etc.
When this global network is available, all trials could be
traced and data could be searched, thus ensuring that the
data are fully transparent to the public.
Conclusion
Existing efforts for trial registration and data transpar-
ency are not enough. They cannot compel all trial investi-
gators to register their trials, and disseminate their trial
results in an accurate and timely manner . Each country
should legislate to develop a mandatory system, and a
network involving all countries should be established,
thus ensuring data transparency to restore the public
confidence in the clinical trial. This system would best
serve the interests of the public, the research community,
and patients who are, ultimately, ourselves.
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